3Stephanie L, Thomas S, Frederike B, et al. Carvedilol therapy in pediatric patients witll congestive heart failure: a study investigating clinical and pharmacokinetic parameters[J]. Am Heart J, 2002,143 (9) .. 916-922.
4Nir A, Nasser N. Clinical value of NT-ProBNP and BNP in podiatric cardiology[J]. Card Fail, 2005,11 (5 Suppl) : 76-80.
5Westerlind A, Wahlander H, Lindstedt G, et al. Clinical signs of heart failure are associated with increased levels of natri- uretic peptide types B and A in childen with congenital heart defects or cardionyopathy[J]. Acta Paediatr,2004,93(3):340- 345.
6Ohuchi H, Takasugi H, Ohashi H, et al. Stratification of pedi- atric heart failure on the basis of neurohormonal and cardiac autonomic nervous acfivities in patients with congenital heart disease[J]. Circulation, 2003,108(12) : 2368-2376.
7Maisel AS,Krishnaswamy P,Nowak RM,et al.Rapid measurement of Btype natriuretic peptide in the emergency diagnosis of heart failure.N Engl J Med,2002,347(3):161-167.
8Mueller C,Scholer A,lanle-kilian K,et al.Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea.N Engl J Med,2004,350(7):647-654.
9Januzzi JL,Kimmenade RV,Lainchbury J,et al.NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure:an international pooled analysis of 1256 patients,The international collaborative of NT-proBNP study.Eur heart J,2006,27:330-337.
10Zaphiriou A,Robb S,Murray-Thomas T,et al.The diagnostic accuracy of plasma BNP and NTproBNP in patients referred from primary care with suspected heart failure:results of the UK natriuretic peptide study.Eur J Heart Fail,2005,7(4):537-541.
